Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 47 h ago

Rapport Therapeutics, Inc.: Cormorant Asset Management, LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Cormorant Asset Management amended its Schedule 13G filing for Rapport Therapeutics, disclosing a revised passive stake in the clinical-stage biotech. The filing, submitted under SEC accession 0001172661-26-005299, updates the investment firm's previously reported ownership position. Schedule 13G amendments are typically triggered when a holder's stake crosses 5% thresholds or when previously reported figures change materially. The revision matters because it signals a shift in Cormorant's exposure to Rapport, a company developing precision medicines for neurological disorders. Investors will watch for further 13G or 13D filings to gauge whether Cormorant's position continues to change.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Cormorant Asset Management, LP, Rapport Therapeutics, Inc.